اعلام University of Babylon | PhD Dissertation at the University of Babylon on Breast Cancer Patients

اعلام University of Babylon - كلية الادارة والاقتصاد

PhD Dissertation at the University of Babylon on Breast Cancer Patients

By : Zaynab Kadhim Ameen Awadh

Date : 10/9/2025 11:51:10 AM

PhD Dissertation at the University of Babylon on Breast Cancer Patients
As part of the activities of the Department of Clinical Biochemistry, the College of Medicine at the University of Babylon held a defense session for the master’s thesis of student Fatimah Jassim Mohammed, entitled:
“Estimation of Estrogen Receptor Tyrosine Kinase and Visfatin Gene Polymorphism in Breast Cancer Patients.”
The thesis was supervised by Asst. Prof. Dr. Ban Mahmoud Shakir and Asst. Prof. Dr. Mushtaq Qahtan Mohammed.
The session was attended by the Head of the Department, Prof. Dr. Tareq Hussein Mugeer, along with several faculty members, researchers, academics, and postgraduate students.
During her defense, the researcher explained that breast cancer (BC) is a malignancy that develops in breast cells. The decline in breast cancer–related mortality is largely attributed to early detection, the adoption of new and personalized treatment approaches, and a better understanding of the disease.
This study specifically focused on breast cancer and aimed to evaluate the roles of tyrosine kinase, visfatin, and gene polymorphism in disease pathogenesis. It also explored the interrelationships among these biochemical parameters and investigated the potential of visfatin and rs1319501 as predictive biomarkers for early detection and monitoring of breast cancer.
• Methodology:
• Serum levels of tyrosine kinase and visfatin were measured using enzyme-linked immunosorbent assay (ELISA).
• Zinc concentrations were assessed using colorimetric methods.
• rs1319501 was determined using the RFLP technique.
• Results:
• A significant decrease in zinc levels was found in breast cancer patients compared to the healthy control group.
• A marked increase in tyrosine kinase levels was also observed.
Conclusion:
Both visfatin and rs1319501 may serve as useful biomarkers for monitoring breast cancer.